Ibutamoren MK-677 - Zyvex Pharmaceuticals
Ibutamoren MK-677 - Zyvex Pharmaceuticals Overview
Ibutamoren MK-677 by Zyvex Pharmaceuticals is a ghrelin receptor agonist and growth hormone secretagogue - a compound that stimulates the pituitary gland to produce and release growth hormone by mimicking the action of ghrelin, the body's natural hunger hormone. Despite being sold alongside SARMs and routinely categorized with them for commercial convenience, MK-677 is not a SARM - it does not bind to androgen receptors, has no direct effect on testosterone or estrogen, and requires no post-cycle therapy. Each tablet contains 25 mg of Ibutamoren, formulated for once-daily oral administration.
MK-677 was originally developed by Merck and later Reverse Pharmacology as a potential treatment for growth hormone deficiency, muscle wasting in the elderly, and osteoporosis. Unlike injectable recombinant human growth hormone (rHGH), MK-677 does not introduce exogenous GH directly - instead it amplifies the body's own GH pulses, producing elevated but physiologically patterned GH and downstream IGF-1 output. This mechanism, combined with oral bioavailability and a 24-hour half-life, makes it one of the most practical GH-raising compounds available. In the athlete community it is used for lean muscle growth, improved recovery, dramatically better sleep quality, and as a long-term anti-aging and body composition tool.
About the Compound: Ibutamoren MK-677 25 mg
MK-677 works by binding to and activating GHSR (growth hormone secretagogue receptors), which are found in the pituitary gland and hypothalamus. This binding mimics the action of ghrelin and triggers GH release from the pituitary - not a single flat infusion like an injection, but amplified natural pulsatile GH release. The pituitary still controls the output; MK-677 increases the amplitude of each pulse and the number of GH pulses per day. Elevated GH then signals the liver to produce more IGF-1 (insulin-like growth factor 1), which is responsible for most of the anabolic, recovery, and body composition effects attributed to growth hormone.
Zyvex Pharmaceuticals produces Ibutamoren at 25 mg per tablet, 100 tablets per pack. The half-life of MK-677 is approximately 24 hours, making once-daily dosing sufficient for stable blood levels and consistent GH elevation. Unlike injectable HGH protocols that require refrigeration and daily or twice-daily injections, MK-677 is taken as a single oral tablet - a practical advantage that has driven its widespread use in the bodybuilding and longevity communities.
What MK-677 Does
All of MK-677's effects flow from one mechanism: elevated GH and downstream IGF-1. Unlike anabolic steroids or true SARMs, MK-677 does not bind androgen receptors - its anabolic and recovery effects are mediated entirely through the GH-IGF-1 axis. The compound produces a broad and distinct set of effects that make it useful across multiple goals simultaneously.
- GH and IGF-1 elevation - MK-677 increases mean 24-hour GH levels and IGF-1 in a dose-dependent fashion. Studies in healthy adults and elderly subjects show 40-80% increases in IGF-1 levels at 25 mg/day. This sustained elevation is the source of all downstream benefits and is the defining pharmacological effect of the compound.
- Sleep quality improvement - The most immediately noticeable effect for most users. GH is primarily released during deep slow-wave sleep, and MK-677 significantly amplifies this nocturnal pulse. Users consistently report deeper, more restorative sleep and more vivid dreams within the first week of use. For athletes, this alone produces measurable recovery benefits - muscle repair and CNS recovery both depend on the quality of deep sleep.
- Lean muscle growth and nitrogen retention - MK-677 improves nitrogen balance, which is the fundamental marker of net muscle protein synthesis. Over a cycle of 8-16 weeks, users running MK-677 alongside training report lean mass gains that are slower and drier than anabolic steroid gains but also more permanent - lean tissue built under GH-IGF-1 influence is not dependent on maintaining supraphysiological hormone levels to be retained.
- Fat loss and body composition - GH is lipolytic - it drives fat mobilization from adipose tissue. Sustained elevation of GH through MK-677 use shifts body composition favorably over time, reducing fat mass while preserving or adding lean mass. This effect is particularly pronounced in users who are already lean and using MK-677 in a maintenance or slight deficit phase.
- Bone density and joint health - IGF-1 is a primary driver of bone mineral density and connective tissue health. Long-term MK-677 use (12+ weeks) supports bone density, improves joint resilience, and contributes to connective tissue quality - useful for aging athletes or those recovering from injury.
- Skin and hair quality - A commonly reported cosmetic benefit of GH elevation. Users report improved skin thickness, hydration, and elasticity, and some report improved hair quality. These are genuine GH effects documented in clinical GH replacement therapy literature.
Not a SARM: MK-677 does not bind to androgen receptors, does not affect testosterone, LH, FSH, or any part of the hypothalamic-pituitary-testicular axis. There is no endocrine suppression, no estrogen conversion, and no PCT required. It is grouped with SARMs on retail sites for commercial organization, not because of pharmacological similarity to compounds like LGD-4033 or RAD-140.
Dosing and Timing
Standard Dose
The established dose range is 10-25 mg per day. Most experienced users run 25 mg daily - the dose at which IGF-1 elevation is most consistent and the full range of effects is reliably produced. New users can start at 10 mg for the first 2 weeks to assess appetite and water retention response before moving to 25 mg. Doses above 25 mg daily are documented in clinical research but show diminishing additional IGF-1 response and increased side effect burden - there is no advantage to exceeding 25 mg for performance purposes.
Timing
Take MK-677 before bed for the strongest effect. GH secretion is naturally concentrated during the first few hours of deep sleep, and dosing MK-677 30-60 minutes before sleep synchronizes peak drug effect with this window, amplifying the nocturnal GH pulse. This timing also means the strongest side effects - appetite stimulation and initial fatigue - occur during sleep rather than during productive hours. Some users split the dose (half morning, half evening) when running 25 mg to spread the appetite effect across the day, but this is a personal preference rather than a pharmacological necessity.
Cycle Length
MK-677 is typically run for 8-16 weeks, and many users run it continuously for 6-12 months for body composition and longevity goals. Unlike anabolic steroids and SARMs, MK-677 has no endocrine suppression to recover from, so extended use is not complicated by the PCT and washout requirements of androgen-active compounds. The limiting factor in cycle length is the blood glucose and insulin resistance effect that becomes more significant with longer duration at higher doses - users running MK-677 continuously should monitor fasting blood glucose quarterly.
Who Uses It and Why
| Use Case | Why MK-677 Works | Typical Protocol |
|---|---|---|
| Lean bulking | GH-IGF-1 elevation improves nitrogen retention and supports lean mass accrual without the water retention of anabolic steroids. MK-677 water retention is initial and frontloaded; gains after week 4 are largely lean tissue. | 25 mg/day before bed, 12-16 weeks. Stack with LGD-4033 or RAD-140 for enhanced anabolic stimulus. Monitor appetite and adjust calories to avoid excessive fat gain from increased hunger. |
| Body recomposition | GH is both anabolic (muscle) and lipolytic (fat). MK-677's sustained GH elevation allows simultaneous muscle gain and fat loss, particularly in users eating at maintenance. This effect is gradual but consistent over 12-16 week cycles. | 25 mg/day, 12-16 weeks at maintenance calories. Stack with Cardarine for additional fat oxidation support. Does not require anabolics to produce measurable recomposition. |
| Sleep and recovery optimization | MK-677's amplification of the nocturnal GH pulse produces the deepest and most consistent sleep quality improvement of any compound in this category. CNS and muscle recovery both depend heavily on slow-wave sleep quality. | 10-25 mg before bed. This use case alone justifies MK-677 as an addition to any anabolic or SARM cycle. Even at 10 mg/day the sleep improvement is significant for most users. |
| Addition to steroid or SARM cycles | MK-677 adds GH-axis support to any anabolic cycle without affecting the hormonal dynamics of the other compounds. It complements testosterone or nandrolone cycles by adding recovery quality and connective tissue support; it complements SARMs by providing GH effects that androgen-active compounds do not produce. | 25 mg/day throughout the anabolic or SARM cycle. Can continue through PCT since it does not affect HPTA recovery. |
| Anti-aging and longevity | GH and IGF-1 decline significantly with age. MK-677 produces IGF-1 levels in elderly subjects comparable to those seen in younger adults. Long-term use supports bone density, muscle mass, skin quality, and cognitive function. | 10-25 mg/day continuously or in extended cycles (6-12 months). Quarterly bloodwork including fasting glucose and IGF-1 levels. This use case benefits most from the lower 10 mg dose to minimize insulin resistance risk over time. |
Side Effects
| Side Effect | Background | Management |
|---|---|---|
| Water retention | The most common side effect, most pronounced in the first 2-4 weeks of use. MK-677 elevates GH, which promotes water and sodium retention through renal mechanisms. Users typically report 2-4 lbs of scale weight increase that is not fat. The effect tapers significantly after week 4 as the body adjusts to the new GH baseline. | Reduce sodium intake in weeks 1-4. The retention resolves on its own - no diuretics needed. If aesthetics are a concern during this period, start with 10 mg rather than 25 mg to reduce the initial water load. |
| Appetite stimulation | MK-677 is a ghrelin agonist - ghrelin is the primary hunger hormone. Strong appetite stimulation is a pharmacological consequence of the mechanism, not a variable side effect. Users report significantly increased hunger, particularly in the 2-4 hours after dosing. This is an advantage for those in a lean bulk phase and a disadvantage for those cutting. | Dose before bed to sleep through the peak appetite window. Users cutting on MK-677 should plan meals proactively and use high-volume, low-calorie foods to manage hunger. The appetite effect typically diminishes somewhat after the first 2-3 weeks as tolerance to ghrelin stimulation develops. |
| Fatigue and lethargy | Some users experience initial fatigue, particularly in the first 1-2 weeks of use. This is associated with the GH pulse timing effect and improved deep sleep quality - users are sleeping more deeply and may feel groggier initially before adapting to the improved sleep architecture. | Dose exclusively before bed (not in the morning). The fatigue effect typically resolves within 2 weeks as the body adapts. Users who dose in the morning or split doses are more likely to experience daytime tiredness. |
| Insulin resistance and blood glucose elevation | GH is counter-regulatory to insulin - it reduces insulin sensitivity at the cellular level. Sustained GH elevation from MK-677 produces a measurable reduction in insulin sensitivity, particularly at 25 mg doses over extended cycles. Fasting blood glucose can rise, and in users with borderline glucose metabolism this can become clinically significant. This is the most underreported side effect in the community and the primary reason MK-677 long-term use requires bloodwork monitoring. | Monitor fasting blood glucose at baseline, at 6-8 weeks, and at cycle end. Keep dietary carbohydrate quality high and avoid high-glycemic meals around the dosing window. Users with pre-existing insulin resistance or family history of type 2 diabetes should use MK-677 at the lowest effective dose (10 mg) and monitor quarterly. The effect is dose-dependent and reversible on discontinuation. |
| Carpal tunnel symptoms | GH excess produces carpal tunnel syndrome as a known side effect - this is documented in clinical GH replacement therapy literature. At MK-677 athletic doses (10-25 mg/day) it is infrequent, but users running higher doses or with pre-existing wrist issues may notice numbness, tingling, or weakness in the hands and wrists. | Reduce dose to 10 mg if carpal tunnel symptoms appear. Symptoms are reversible on dose reduction or discontinuation. Wrist support during training can help manage discomfort while adjusting protocol. |
Stacking MK-677
MK-677's non-androgenic, non-suppressive mechanism makes it compatible with virtually any compound - anabolic steroids, SARMs, peptides, or standalone. It adds GH-axis support that no androgen-active compound provides, making it genuinely additive rather than redundant in most stacks.
| Stack | Purpose | Notes |
|---|---|---|
| MK-677 + LGD-4033 | The most popular SARM stack. LGD-4033 provides androgenic anabolic stimulus (muscle, strength); MK-677 adds GH-IGF-1 elevation, sleep quality, and connective tissue support. Together they produce lean bulking results that exceed what either compound delivers alone. | MK-677 25 mg before bed + LGD-4033 5-10 mg in the morning, 8-12 weeks. LGD-4033 requires a light PCT (Nolvadex 20 mg x 4 weeks). MK-677 can continue through PCT since it does not affect HPTA recovery. |
| MK-677 + RAD-140 | The most anabolic SARM combination. RAD-140 at 15-20 mg produces significant strength and mass gains; MK-677 adds recovery quality and GH support to offset the cardiovascular strain some users experience on RAD-140. | MK-677 25 mg before bed + RAD-140 10-15 mg in the morning, 8 weeks. RAD-140 is suppressive and requires PCT. Monitor blood pressure during the cycle - both compounds can contribute to elevated BP in susceptible users. |
| MK-677 + Testosterone (anabolic cycle) | Adding MK-677 to a testosterone base cycle provides GH-axis support, improved sleep quality during the cycle, and connective tissue benefits. This combination is used by intermediate and advanced users who want the full hormonal stack - androgens for muscle, GH for recovery and body composition. | MK-677 25 mg before bed throughout the testosterone cycle. Can continue through PCT. Does not interact with AI, SERM, or any cycle support compound. Monitor blood glucose if cycle includes heavy bulking calories. |
| MK-677 + BPC-157 | A recovery-focused peptide stack. BPC-157 handles local tissue repair at injury sites through growth factor receptor upregulation; MK-677 provides systemic GH-IGF-1 elevation that accelerates connective tissue healing, improves sleep, and supports full-body recovery. Used by athletes managing chronic injuries or high training loads. | MK-677 25 mg before bed + BPC-157 200-300 mcg/day (SubQ or near injury site). No PCT, no hormonal management required. Can be run alongside any other compound without interaction. |
Frequently Asked Questions
What is Ibutamoren MK-677 and how does it work?
Ibutamoren MK-677 by Zyvex Pharmaceuticals is a ghrelin receptor agonist and growth hormone secretagogue. It works by binding to GHSR (growth hormone secretagogue receptors) in the pituitary gland and hypothalamus, mimicking the action of ghrelin - the body's natural hunger hormone - and triggering the pituitary to release growth hormone. Unlike injectable recombinant HGH, which delivers exogenous GH directly, MK-677 amplifies the body's own natural GH pulses. The result is elevated GH and downstream IGF-1 production throughout the day, particularly during sleep when GH release is naturally concentrated. Each tablet contains 25 mg of Ibutamoren. The compound has a half-life of approximately 24 hours, making once-daily dosing sufficient to maintain stable blood levels and consistent GH elevation.
Is MK-677 a SARM? What is the difference?
No - MK-677 is not a SARM. The distinction matters pharmacologically. SARMs (Selective Androgen Receptor Modulators) work by binding to androgen receptors in muscle and bone tissue to produce anabolic effects. They mimic testosterone at the receptor level and, as a result, suppress natural testosterone production to varying degrees, requiring post-cycle therapy. MK-677 operates through an entirely different mechanism - it is a ghrelin receptor agonist that acts on the GH axis, not the androgen axis. It does not bind androgen receptors, does not affect testosterone production, and does not suppress LH or FSH. No PCT is needed after MK-677 use. The compound is sold alongside SARMs on retail platforms because they are marketed to the same audience and used in similar contexts, not because they share pharmacological properties. The grouping is commercial, not scientific.
Does MK-677 require PCT after a cycle?
No - MK-677 does not require post-cycle therapy. Because it does not bind androgen receptors and has no effect on the hypothalamic-pituitary-testicular axis, there is no testosterone suppression to recover from. LH, FSH, and endogenous testosterone production are unaffected by MK-677 use at any dose. PCT medications (Clomid, Nolvadex) are not relevant and not needed. This is a genuine advantage over SARMs and anabolic steroids, which all require some degree of hormonal recovery after a cycle. MK-677 can also be continued through PCT if it is being run alongside a suppressive compound - it does not interfere with HPTA recovery and the GH-axis support and sleep quality benefits remain valuable during the PCT window.
How does MK-677 compare to injectable HGH?
MK-677 and injectable recombinant human growth hormone (rHGH) both raise GH levels but through fundamentally different mechanisms, at different cost points, and with different pharmacokinetic profiles. Injectable HGH delivers exogenous GH directly - it bypasses the pituitary entirely and provides a flat, non-pulsatile GH level that is determined by the dose injected. MK-677 stimulates the pituitary to produce and release GH - the output remains pulsatile and physiologically patterned, with the body retaining some regulatory control over the GH signal. The practical differences: MK-677 is an oral tablet requiring no refrigeration and no injection technique; rHGH requires subcutaneous injections, refrigeration, and sourcing pharmaceutical-grade product. For IGF-1 elevation and most GH-mediated benefits at bodybuilding doses, MK-677 at 25 mg/day produces comparable IGF-1 increases to moderate rHGH doses (2-4 IU/day) at a fraction of the cost and complexity. The advantage of rHGH is precise dose control and a predictable flat GH profile; the advantage of MK-677 is convenience, oral bioavailability, and cost.
Why should MK-677 be taken before bed rather than in the morning?
GH secretion in the body is pulsatile and strongly concentrated during deep slow-wave sleep, particularly in the first 1-3 hours after sleep onset. This nocturnal GH pulse accounts for the majority of daily GH output in healthy adults. When MK-677 is dosed 30-60 minutes before bed, peak drug effect coincides with the beginning of deep sleep, amplifying this natural nocturnal pulse at its most productive window. The result is a stronger and more physiologically aligned GH response compared to morning dosing, which hits peak drug effect during waking hours when GH release is naturally lower. There is also a practical benefit: the two most noticeable side effects of MK-677 - intense appetite stimulation and initial fatigue - occur during sleep when dosed at bedtime rather than during working hours. Morning dosing means managing strong hunger and potential grogginess during the day.
What side effects should I expect with MK-677?
The most common side effects of MK-677 are water retention, appetite stimulation, and initial fatigue - all of which are direct consequences of the compound's mechanism rather than toxicity. Water retention is most pronounced in the first 2-4 weeks of use as the body adjusts to elevated GH levels; it typically decreases significantly after this period and is not fat gain. Appetite stimulation is a pharmacological effect of ghrelin receptor activation - ghrelin is the hunger hormone, and agonizing its receptor produces strong hunger signals, particularly in the hours after dosing. Users cutting with MK-677 need to plan around this. Initial fatigue resolves within 1-2 weeks for most users as the body adapts to improved deep sleep. The most clinically significant and underappreciated side effect is reduced insulin sensitivity and elevated fasting blood glucose, particularly at 25 mg doses over extended cycles. This effect is dose-dependent and reversible, but warrants bloodwork monitoring for anyone running MK-677 for more than 8 weeks. Carpal tunnel symptoms can occur at higher doses due to GH-driven fluid retention in the carpal tunnel - dose reduction resolves this.
Can MK-677 cause insulin resistance, and how do I monitor for it?
Yes - insulin resistance is a real and documented side effect of sustained GH elevation, including GH raised by MK-677. Growth hormone is counter-regulatory to insulin: it reduces cellular insulin sensitivity, raises fasting blood glucose, and can push borderline glucose metabolism toward impaired fasting glucose in susceptible users over extended cycles. At 25 mg/day for 8-16 weeks this effect is measurable and reversible on discontinuation, but it should not be ignored. To monitor: get a baseline fasting blood glucose measurement before starting. Recheck at 6-8 weeks and at cycle end. Normal fasting glucose is under 100 mg/dL; impaired fasting glucose is 100-125 mg/dL and should prompt dose reduction to 10 mg or discontinuation. Keep dietary sugar and refined carbohydrates low, particularly in the evening window around dosing. Users with pre-existing insulin resistance, metabolic syndrome, or a family history of type 2 diabetes should use MK-677 at the lowest effective dose (10 mg/day) and monitor quarterly if running continuously.
How long can I run MK-677 and when should I stop?
MK-677 does not have the hard cycle-length ceiling of anabolic steroids or SARMs because it does not suppress the HPTA. Many users run it continuously for 6-12 months for body composition, anti-aging, and recovery benefits. The standard cycle for performance use is 8-16 weeks. The practical limiting factors for longer runs are the insulin resistance effect at 25 mg doses and appetite management on a cut. For extended or indefinite use, 10-15 mg/day is preferred over 25 mg - the IGF-1 elevation is still meaningful, the appetite and glucose effects are significantly more manageable, and long-term tolerability improves. Signs that MK-677 should be paused or discontinued: fasting glucose consistently above 110 mg/dL, significant carpal tunnel symptoms that do not improve with dose reduction, or persistent fatigue beyond the initial 2-week adaptation period.
Related Products
